MARKED REDUCTION IN USE BUT MINIMAL IMPACT FOLLOWING PBS DELISTING OF CINACALCET IN A TERTIARY INSTITUTION

YS RAJARAM1, H DIXON 2, C MCBRIDE3, H GOCK1, 3

1Department of Nephrology; 2Pharmacy Department; 3Department of Medicine, University of Melbourne, St Vincent’s Hospital Melbourne, AUSTRALIA.

Background: Cinacalcet, a patented calcimimetic was PBS-listed 2008-2015 to treat secondary hyperparathyroidism (hPTH) in stage-5D CKD and reputed to improve surrogate biochemical markers of mortality and parathyroidectomy. It was PBS-delisted after the EVOLVE study demonstrated no survival benefit.

Aim: To assess at our centre: (1) Cinacalcet usage before and during PBS-listing and after PBS-de-listing, (2) Biochemical outcomes of patients that initially remained on Cinacalcet post-PBS-delisting,    (3) hPTH parathyroidectomy rate after PBS-delisting.

Methods: Pharmacy records were used to identify patients on Cinacalcet (2006-16).  From the date of PBS-delisting (Aug 1st, 2015), serum Calcium, Phosphate and PTH level were obtained from hospital records.  If Cinacalcet was later ceased, the same parameters were reviewed 3 months post-cessation.  We also identified the annual number of hPTH parathyroidectomy between 2006-2016 to calculate the parathyroidectomy rate [no. of hPTH parathyroidectomy/total dialysis patients] x 100.

Results: The number of patients prescribed Cinacalcet was 10 prior to PBS-listing (2006-7) and peaked at 67 during PBS-listing (2010). There were 21 patients on Cinacalcet after delisting. Among those, 14 (67%) patients subsequently ceased, 3 (14%) proceeded to parathyroidectomy and 4 (19%) remain on Cinacalcet to date. Of those that ceased, the mean serum calcium, phosphate and PTH levels were 2.46±0.19, 1.40±0.47, 383±287 respectively and post-cessation were 2.53±0.21 (p=0.14), 1.34±0.66 (p=0.31), 464±403 (p=0.33) respectively.  The parathyroidectomy rate was 1.73% (2006-7) before PBS-listing, 1.55% (2008-14) while PBS-listed and 2.43% (2015-6) post-PBS-delisting.

Conclusions: No significant change in biochemical profile and PTH was observed with cessation of Cinacalcet and return to standard therapy. However, there was an increased number of hPTH parathyroidectomy following PBS-delisting that we hypothesise will be transient.

About ANZSN

The ASM is hosted by Australian and New Zealand Society of Nephrology.

The aims of the Society are to promote and support the study of the kidney and urinary tract in health and disease, and to ensure the highest professional standards for the practice of nephrology in Australia and New Zealand.

Conference Managers

Please contact the team at Conference Design with any questions regarding the conference.
/wp-content/uploads/2017/08/Conference-Design-400x400.png
© 2015 - 2016 Conference Design Pty Ltd